Advertisement

Index by author

May 01, 1989; Volume 249,Issue 2

A

  1. Abrahams, S L

    1. Trifenagrel: a chemically novel platelet aggregation inhibitor.
      S L Abrahams, R J Hazen, A G Batson and A P Phillips
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 359-365;

  2. Adams, D G

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

  3. Adams, W H

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

  4. Adams, W J

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  5. Ahmad, S

    1. Modulation of pyloric motor activity via adrenergic receptors.
      H D Allescher, S Ahmad, F Kostolanska, C Y Kwan and E E Daniel
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 652-659;

  6. Albrightson-Winslow, C R

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  7. Allescher, H D

    1. Modulation of pyloric motor activity via adrenergic receptors.
      H D Allescher, S Ahmad, F Kostolanska, C Y Kwan and E E Daniel
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 652-659;

  8. Ayres, E A

    1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

B

  1. Bagwell, E E

    1. Stereoselective uptake of atenolol into storage granules isolated from PC12 cells.
      E E Bagwell, J G Webb, T Walle and T E Gaffney
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 476-482;

  2. Bailey, L S

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  3. Baillie, T A

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  4. Balster, R L

    1. Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists.
      J Willetts and R L Balster
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 438-443;

  5. Banet, D E

    1. Potentiation of 3-methylcholanthrene induction of rat hepatic cytochrome P450IA1 by dexamethasone in vivo.
      A J Sherratt, D E Banet, M W Linder and R A Prough
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 667-672;

  6. Barnette, M

    1. Cyclic GMP: a potential mediator of neurally- and drug-induced relaxation of opossum lower esophageal sphincter.
      M Barnette, T J Torphy, M Grous, C Fine and H S Ormsbee
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 524-528;

  7. Batson, A G

    1. Trifenagrel: a chemically novel platelet aggregation inhibitor.
      S L Abrahams, R J Hazen, A G Batson and A P Phillips
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 359-365;

  8. Bentley, R G

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  9. Berlan, M

    1. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists.
      J Galitzky, P Mauriege, M Berlan and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 583-591;
    2. Human fat cell alpha-2 adrenoceptors. II. Comparative study of partial and full agonist binding parameters using [3H]clonidine and [3H]UK-14,304.
      J Galitzky, M Lafontan, H Paris and M Berlan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 592-600;

  10. Bernton, E W

    1. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.
      H U Bryant, J W Holaday and E W Bernton
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 424-429;

  11. Bhaskaran, D

    1. Catechol and indole metabolism in rostral ventrolateral medulla change synchronously with changing blood pressure.
      D Bhaskaran and C R Freed
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 660-666;

  12. Boje, K M

    1. Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat.
      K M Boje and H L Fung
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 567-571;

  13. Bond, R A

    1. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation.
      R A Bond, A G Ornstein and D E Clarke
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 401-410;

  14. Brater, D C

    1. Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
      M P Knadler, D C Brater and S D Hall
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 378-385;

  15. Breimer, D D

    1. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
      J H Schellens, J H van der Wart, M Brugman and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 638-645;

  16. Brier, M E

    1. Pharmacokinetics and pharmacodynamics of atrial natriuretic peptide after bolus and infusion administration in the isolated perfused rat kidney.
      M E Brier and G B Harding
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 372-377;

  17. Brooks, D P

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  18. Brugman, M

    1. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
      J H Schellens, J H van der Wart, M Brugman and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 638-645;

  19. Bryant, H U

    1. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.
      H U Bryant, J W Holaday and E W Bernton
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 424-429;

  20. Burks, T F

    1. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
      J E Shook and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 444-449;
    2. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;
    3. Pharmacological characterization of neural mechanisms regulating mucosal ion transport in mouse jejunum.
      R J Sheldon, M E Malarchik, D A Fox, T F Burks and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 572-582;

  21. Bylund, D B

    1. Characterization of serotonin-1B receptors negatively coupled to adenylate cyclase in OK cells, a renal epithelial cell line from the opossum.
      T J Murphy and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 535-543;

C

  1. Caldwell, N

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  2. Carretero, O A

    1. Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus.
      G G Orce, O A Carretero, G Scicli and A G Scicli
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 470-475;

  3. Cherian, M G

    1. Metabolic changes in glutathione and metallothionein in newborn rat liver.
      K R Gallant and M G Cherian
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 631-637;

  4. Clarke, D E

    1. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation.
      R A Bond, A G Ornstein and D E Clarke
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 401-410;

  5. Crabbe, J C

    1. Sensitivity and tolerance to ethanol-induced hypothermia in genetically selected mice.
      J C Crabbe, D J Feller and J S Dorow
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 456-461;

  6. Craft, R M

    1. Differential cross-tolerance to opioid agonists in morphine-tolerant pigeons responding under a schedule of food presentation.
      R M Craft, M J Picker and L A Dykstra
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 386-393;

D

  1. Danhof, M

    1. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats.
      J Dingemanse, J B van Bree and M Danhof
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 601-608;

  2. Daniel, E E

    1. Modulation of pyloric motor activity via adrenergic receptors.
      H D Allescher, S Ahmad, F Kostolanska, C Y Kwan and E E Daniel
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 652-659;

  3. Dhalla, N S

    1. Activation of heart sarcoplasmic reticulum Ca++-stimulated adenosine triphosphatase by insulin.
      M P Gupta, S L Lee and N S Dhalla
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 623-630;

  4. Dingemanse, J

    1. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats.
      J Dingemanse, J B van Bree and M Danhof
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 601-608;

  5. Dobyan, D

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  6. Dorow, J S

    1. Sensitivity and tolerance to ethanol-induced hypothermia in genetically selected mice.
      J C Crabbe, D J Feller and J S Dorow
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 456-461;

  7. Duff, H J

    1. Mexiletine-quinidine combination: enhanced antiarrhythmic and electrophysiologic activity in the dog.
      H J Duff
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 617-622;

  8. Durley, R C

    1. In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.
      P A Krieter, G M Olins, S P Verrett and R C Durley
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 411-417;

  9. Dykstra, L A

    1. Differential cross-tolerance to opioid agonists in morphine-tolerant pigeons responding under a schedule of food presentation.
      R M Craft, M J Picker and L A Dykstra
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 386-393;
    2. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
      M J Picker and L A Dykstra
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 557-566;

F

  1. Feller, D J

    1. Sensitivity and tolerance to ethanol-induced hypothermia in genetically selected mice.
      J C Crabbe, D J Feller and J S Dorow
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 456-461;

  2. Fine, C

    1. Cyclic GMP: a potential mediator of neurally- and drug-induced relaxation of opossum lower esophageal sphincter.
      M Barnette, T J Torphy, M Grous, C Fine and H S Ormsbee
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 524-528;

  3. Fox, D A

    1. Pharmacological characterization of neural mechanisms regulating mucosal ion transport in mouse jejunum.
      R J Sheldon, M E Malarchik, D A Fox, T F Burks and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 572-582;

  4. Freed, C R

    1. Catechol and indole metabolism in rostral ventrolateral medulla change synchronously with changing blood pressure.
      D Bhaskaran and C R Freed
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 660-666;

  5. Fung, H L

    1. Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat.
      K M Boje and H L Fung
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 567-571;

G

  1. Gaffney, T E

    1. Stereoselective uptake of atenolol into storage granules isolated from PC12 cells.
      E E Bagwell, J G Webb, T Walle and T E Gaffney
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 476-482;

  2. Galitzky, J

    1. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists.
      J Galitzky, P Mauriege, M Berlan and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 583-591;
    2. Human fat cell alpha-2 adrenoceptors. II. Comparative study of partial and full agonist binding parameters using [3H]clonidine and [3H]UK-14,304.
      J Galitzky, M Lafontan, H Paris and M Berlan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 592-600;

  3. Gallant, K R

    1. Metabolic changes in glutathione and metallothionein in newborn rat liver.
      K R Gallant and M G Cherian
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 631-637;

  4. Gesek, F A

    1. Alpha adrenoceptor agonist stimulation of oxygen consumption in rat proximal and distal nephrons.
      F A Gesek and J W Strandhoy
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 529-534;

  5. Gohlke, P

    1. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
      P Gohlke, H Urbach, B Schölkens and T Unger
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 609-616;

  6. Grous, M

    1. Cyclic GMP: a potential mediator of neurally- and drug-induced relaxation of opossum lower esophageal sphincter.
      M Barnette, T J Torphy, M Grous, C Fine and H S Ormsbee
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 524-528;

  7. Gupta, M P

    1. Activation of heart sarcoplasmic reticulum Ca++-stimulated adenosine triphosphatase by insulin.
      M P Gupta, S L Lee and N S Dhalla
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 623-630;

H

  1. Hall, S D

    1. Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
      M P Knadler, D C Brater and S D Hall
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 378-385;

  2. Halstead, G W

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  3. Hamel, L T

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  4. Harding, G B

    1. Pharmacokinetics and pharmacodynamics of atrial natriuretic peptide after bolus and infusion administration in the isolated perfused rat kidney.
      M E Brier and G B Harding
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 372-377;

  5. Harpootlian, H

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  6. Harris, A L

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  7. Hay, D W

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  8. Hazen, R J

    1. Trifenagrel: a chemically novel platelet aggregation inhibitor.
      S L Abrahams, R J Hazen, A G Batson and A P Phillips
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 359-365;

  9. Hisayama, T

    1. Interaction of 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, ryanodine and procaine with muscarinic cholinergic M2 receptor sites in smooth muscle.
      T Hisayama, I Takayanagi, N Kumagai and H Kubo
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 646-651;

  10. Holaday, J W

    1. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.
      H U Bryant, J W Holaday and E W Bernton
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 424-429;
    2. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
      J B Long, A Martinez-Arizala, S H Johnson and J W Holaday
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 499-506;

  11. Holtzclaw, D

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  12. Hoyt, D

    1. Effect of 1,3-bis-(2-chloroethyl)-1-nitrosourea on cholephilic dye metabolism and excretion in anesthetized rats.
      D Hoyt and R E Larson
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 450-455;

  13. Hruby, V J

    1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

  14. Huffman, W F

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  15. Hui, K K

    1. Effects of protein kinase inhibitor, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, on beta-2 adrenergic receptor activation and desensitization in intact human lymphocytes.
      K K Hui and J L Yu
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 492-498;

J

  1. Johnson, S H

    1. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
      J B Long, A Martinez-Arizala, S H Johnson and J W Holaday
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 499-506;

K

  1. Kaiser, D G

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  2. Kazmierski, W

    1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

  3. Kimes, A S

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  4. Kinter, L B

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  5. Knadler, M P

    1. Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
      M P Knadler, D C Brater and S D Hall
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 378-385;

  6. Kostolanska, F

    1. Modulation of pyloric motor activity via adrenergic receptors.
      H D Allescher, S Ahmad, F Kostolanska, C Y Kwan and E E Daniel
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 652-659;

  7. Kramer, T H

    1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

  8. Krieter, P A

    1. In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.
      P A Krieter, G M Olins, S P Verrett and R C Durley
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 411-417;

  9. Kubo, H

    1. Interaction of 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, ryanodine and procaine with muscarinic cholinergic M2 receptor sites in smooth muscle.
      T Hisayama, I Takayanagi, N Kumagai and H Kubo
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 646-651;

  10. Kumagai, N

    1. Interaction of 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, ryanodine and procaine with muscarinic cholinergic M2 receptor sites in smooth muscle.
      T Hisayama, I Takayanagi, N Kumagai and H Kubo
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 646-651;

  11. Kumor, K

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  12. Kwan, C Y

    1. Modulation of pyloric motor activity via adrenergic receptors.
      H D Allescher, S Ahmad, F Kostolanska, C Y Kwan and E E Daniel
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 652-659;

L

  1. Lafontan, M

    1. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists.
      J Galitzky, P Mauriege, M Berlan and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 583-591;
    2. Human fat cell alpha-2 adrenoceptors. II. Comparative study of partial and full agonist binding parameters using [3H]clonidine and [3H]UK-14,304.
      J Galitzky, M Lafontan, H Paris and M Berlan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 592-600;

  2. Larson, R E

    1. Effect of 1,3-bis-(2-chloroethyl)-1-nitrosourea on cholephilic dye metabolism and excretion in anesthetized rats.
      D Hoyt and R E Larson
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 450-455;

  3. Lee, S L

    1. Activation of heart sarcoplasmic reticulum Ca++-stimulated adenosine triphosphatase by insulin.
      M P Gupta, S L Lee and N S Dhalla
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 623-630;

  4. Lemp, B M

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  5. Linder, M W

    1. Potentiation of 3-methylcholanthrene induction of rat hepatic cytochrome P450IA1 by dexamethasone in vivo.
      A J Sherratt, D E Banet, M W Linder and R A Prough
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 667-672;

  6. Long, J B

    1. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
      J B Long, A Martinez-Arizala, S H Johnson and J W Holaday
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 499-506;

M

  1. Malarchik, M E

    1. Pharmacological characterization of neural mechanisms regulating mucosal ion transport in mouse jejunum.
      R J Sheldon, M E Malarchik, D A Fox, T F Burks and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 572-582;

  2. Martinez-Arizala, A

    1. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
      J B Long, A Martinez-Arizala, S H Johnson and J W Holaday
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 499-506;

  3. Mauriege, P

    1. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists.
      J Galitzky, P Mauriege, M Berlan and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 583-591;

  4. McCullough, K

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  5. Mehta, A K

    1. Benzodiazepine and beta-carboline interactions with GABAA receptor-gated chloride channels in mammalian cultured spinal cord neurons.
      A K Mehta and M K Ticku
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 418-423;

  6. Murphy, T J

    1. Characterization of serotonin-1B receptors negatively coupled to adenylate cyclase in OK cells, a renal epithelial cell line from the opossum.
      T J Murphy and D B Bylund
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 535-543;

N

  1. Newton, J F

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  2. Nunan, L

    1. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
      R J Sheldon, L Nunan and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 462-469;

O

  1. Olanoff, L S

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  2. Olins, G M

    1. In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.
      P A Krieter, G M Olins, S P Verrett and R C Durley
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 411-417;

  3. Orce, G G

    1. Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus.
      G G Orce, O A Carretero, G Scicli and A G Scicli
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 470-475;

  4. Ormsbee, H S

    1. Cyclic GMP: a potential mediator of neurally- and drug-induced relaxation of opossum lower esophageal sphincter.
      M Barnette, T J Torphy, M Grous, C Fine and H S Ormsbee
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 524-528;

  5. Ornstein, A G

    1. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation.
      R A Bond, A G Ornstein and D E Clarke
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 401-410;

  6. Osborn, R R

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

P

  1. Paris, H

    1. Human fat cell alpha-2 adrenoceptors. II. Comparative study of partial and full agonist binding parameters using [3H]clonidine and [3H]UK-14,304.
      J Galitzky, M Lafontan, H Paris and M Berlan
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 592-600;

  2. Perrone, M H

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  3. Phillips, A P

    1. Trifenagrel: a chemically novel platelet aggregation inhibitor.
      S L Abrahams, R J Hazen, A G Batson and A P Phillips
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 359-365;

  4. Picker, M J

    1. Differential cross-tolerance to opioid agonists in morphine-tolerant pigeons responding under a schedule of food presentation.
      R M Craft, M J Picker and L A Dykstra
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 386-393;
    2. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
      M J Picker and L A Dykstra
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 557-566;

  5. Porreca, F

    1. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
      R J Sheldon, L Nunan and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 462-469;
    2. Pharmacological characterization of neural mechanisms regulating mucosal ion transport in mouse jejunum.
      R J Sheldon, M E Malarchik, D A Fox, T F Burks and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 572-582;

  6. Prough, R A

    1. Potentiation of 3-methylcholanthrene induction of rat hepatic cytochrome P450IA1 by dexamethasone in vivo.
      A J Sherratt, D E Banet, M W Linder and R A Prough
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 667-672;

R

  1. Read, H

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

S

  1. Schellens, J H

    1. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
      J H Schellens, J H van der Wart, M Brugman and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 638-645;

  2. Schölkens, B

    1. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
      P Gohlke, H Urbach, B Schölkens and T Unger
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 609-616;

  3. Scicli, A G

    1. Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus.
      G G Orce, O A Carretero, G Scicli and A G Scicli
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 470-475;

  4. Scicli, G

    1. Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus.
      G G Orce, O A Carretero, G Scicli and A G Scicli
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 470-475;

  5. Sheldon, R J

    1. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
      R J Sheldon, L Nunan and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 462-469;
    2. Pharmacological characterization of neural mechanisms regulating mucosal ion transport in mouse jejunum.
      R J Sheldon, M E Malarchik, D A Fox, T F Burks and F Porreca
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 572-582;

  6. Sherratt, A J

    1. Potentiation of 3-methylcholanthrene induction of rat hepatic cytochrome P450IA1 by dexamethasone in vivo.
      A J Sherratt, D E Banet, M W Linder and R A Prough
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 667-672;

  7. Shook, J E

    1. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
      J E Shook and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 444-449;
    2. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

  8. Siegelman, H W

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

  9. Silver, P J

    1. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
      A L Harris, B M Lemp, R G Bentley, M H Perrone, L T Hamel and P J Silver
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 394-400;

  10. Slatkin, D N

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

  11. Spector, D

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  12. Stassen, F L

    1. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
      C R Albrightson-Winslow, N Caldwell, D P Brooks, W F Huffman, F L Stassen and L B Kinter
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 366-371;

  13. Stoner, R D

    1. Prophylaxis of cyanobacterial and mushroom cyclic peptide toxins.
      W H Adams, R D Stoner, D G Adams, H Read, D N Slatkin and H W Siegelman
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 552-556;

  14. Strandhoy, J W

    1. Alpha adrenoceptor agonist stimulation of oxygen consumption in rat proximal and distal nephrons.
      F A Gesek and J W Strandhoy
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 529-534;

T

  1. Takayanagi, I

    1. Interaction of 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride, ryanodine and procaine with muscarinic cholinergic M2 receptor sites in smooth muscle.
      T Hisayama, I Takayanagi, N Kumagai and H Kubo
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 646-651;

  2. Teller, D

    1. Effects of acute and chronic acyclovir on canine renal function.
      A S Kimes, K Kumor, K McCullough, D Holtzclaw, D Teller, D Dobyan and D Spector
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 483-491;

  3. Ticku, M K

    1. Benzodiazepine and beta-carboline interactions with GABAA receptor-gated chloride channels in mammalian cultured spinal cord neurons.
      A K Mehta and M K Ticku
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 418-423;

  4. Torphy, T J

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;
    2. Cyclic GMP: a potential mediator of neurally- and drug-induced relaxation of opossum lower esophageal sphincter.
      M Barnette, T J Torphy, M Grous, C Fine and H S Ormsbee
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 524-528;

U

  1. Underwood, D C

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  2. Unger, T

    1. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
      P Gohlke, H Urbach, B Schölkens and T Unger
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 609-616;

  3. Urbach, H

    1. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
      P Gohlke, H Urbach, B Schölkens and T Unger
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 609-616;

V

  1. van Bree, J B

    1. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats.
      J Dingemanse, J B van Bree and M Danhof
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 601-608;

  2. van der Wart, J H

    1. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
      J H Schellens, J H van der Wart, M Brugman and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 638-645;

  3. Van Giessen, G J

    1. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.
      T A Baillie, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian and G J Van Giessen
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 517-523;

  4. Verrett, S P

    1. In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.
      P A Krieter, G M Olins, S P Verrett and R C Durley
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 411-417;

  5. Vickery-Clark, L

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

W

  1. Walle, T

    1. Stereoselective uptake of atenolol into storage granules isolated from PC12 cells.
      E E Bagwell, J G Webb, T Walle and T E Gaffney
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 476-482;

  2. Wasserman, M A

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  3. Webb, J G

    1. Stereoselective uptake of atenolol into storage granules isolated from PC12 cells.
      E E Bagwell, J G Webb, T Walle and T E Gaffney
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 476-482;

  4. Weiss, B

    1. Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice.
      J D Winkler and B Weiss
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 507-516;

  5. Willetts, J

    1. Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists.
      J Willetts and R L Balster
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 438-443;

  6. Winkler, J D

    1. Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice.
      J D Winkler and B Weiss
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 507-516;

  7. Wire, W S

    1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
      T H Kramer, J E Shook, W Kazmierski, E A Ayres, W S Wire, V J Hruby and T F Burks
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 544-551;

Y

  1. Yodis, L A

    1. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes.
      T J Torphy, J F Newton, M A Wasserman, L Vickery-Clark, R R Osborn, L S Bailey, L A Yodis, D C Underwood and D W Hay
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 430-437;

  2. Yu, J L

    1. Effects of protein kinase inhibitor, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, on beta-2 adrenergic receptor activation and desensitization in intact human lymphocytes.
      K K Hui and J L Yu
      Journal of Pharmacology and Experimental Therapeutics May 1989, 249 (2) 492-498;
Back to top

In this issue